Current Illinois CancerCare Clinical Trials

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Study Number: BGB-11417-301

Study Summary:
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)

Status: Open

Open in Bloomington, Galesburg, Ottawa, Pekin, Peoria, Peru, and Washington

Study Coordinator(s)
  • Navigator Heather, 309-243-3661
  • Hannah, 309-243-3628

Study Link

« Search Again